Supriya Lifescience Limited

NSE SUPRIYA.NS

Supriya Lifescience Limited Gross Profit for the year ending March 31, 2024: USD 25.27 M

Supriya Lifescience Limited Gross Profit is USD 25.27 M for the year ending March 31, 2024, a -25.84% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Supriya Lifescience Limited Gross Profit for the year ending March 31, 2023 was USD 34.08 M, a -10.60% change year over year.
Supriya Lifescience Limited Gross Profit for the year ending March 31, 2022 was USD 38.13 M, a 19.20% change year over year.
Supriya Lifescience Limited Gross Profit for the year ending March 31, 2021 was USD 31.98 M, a 61.87% change year over year.
Supriya Lifescience Limited Gross Profit for the year ending March 31, 2020 was USD 19.76 M, a 31.62% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NSE: SUPRIYA.NS

Supriya Lifescience Limited

CEO	Dr. Satish Waman Wagh
IPO Date	Dec. 28, 2021
Location	India
Headquarters	207/208 Udyog Bhavan
Employees	448
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, antihypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.

Key trends

Past 5 years